Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to COVID-19 Vaccine in MS Patients on Teriflunomide or Alemtuzumab
NCT05075499Phase 4Unknown
- Sponsor
- Sheba Medical Center
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of teriflunomide, alemtuzumab in multiple sclerosis (MS), sponsored by Sheba Medical Center. Status: unknown.
02
Drugs
teriflunomidealemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05075499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075499.